Septic Shock clinical trials at UCSF

2 research studies open to eligible people

Showing trials for

  • Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study

    open to eligible people ages 18 years and up

    Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock

    San Francisco, California and other locations

  • Stress Hydrocortisone In Pediatric Septic Shock

    open to eligible people ages 1 month to 17 years

    SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and vasoactive-inotropic refractory septic shock. It is hypothesized that adjunctive hydrocortisone will significantly reduce the proportion of children with poor outcomes, defined as death or severely impaired health-related quality of life (HRQL), as assessed at 28 days following study enrollment (randomization).

    Oakland, California and other locations